
🚨 New data at #ASCO2026: First-in-class RNA-targeting therapy #STC15 shows early activity in #sarcoma. 📅 June 1, 1:30–4:30 PM CDT 🔗 Read more: bit.ly/3PwODTa

STORM Therapeutics is a biotech company discovering and developing novel small molecule therapies for RNA modification enzymes for oncology and other diseases

🚨 New data at #ASCO2026: First-in-class RNA-targeting therapy #STC15 shows early activity in #sarcoma. 📅 June 1, 1:30–4:30 PM CDT 🔗 Read more: bit.ly/3PwODTa

📢 We’ve announced a $56 million Series C financing to support the advancement of STC‑15, our first‑in‑class, oral small‑molecule METTL3 inhibitor. The first patient has now been dosed in a Phase 2 monotherapy trial in selected sarcoma indications. bit.ly/3QeVxMH

Excited to team up with AlidaBio to explore how METTL3 inhibition affects RNA regulation in cancer patients. We're using AlidaBio's advanced sequencing platforms to analyze samples from our Phase 1/2 trials with STC-15, our first-in-class METTL3 inhibitor. bit.ly/49tpJd5

Meet STORM at @ELRIG_SCIENCE Drug Discovery 2025! Join us for our poster presentations to explore the critical role of RNA-binding proteins in cellular replication stress mechanisms. 📍 Poster #163 📅 21 & 22 Oct 🕐 13:00-13:45 BST 📌 Beside the Tech Theatre


📣 Appointment news from STORM! We're excited to welcome veteran cancer drug developer Eric Martin as Chief Development Officer as we advance our METTL3 inhibitor STC-15 through Phase 1b/2 development.🔗 Learn more: bit.ly/44yokjU #oncology #biotech #drugdevelopment

Clinical milestone achieved & CMO appointed! The #firstpatient has been dosed in our collaboration with Coherus Biosciences, commencing a Phase 1b/2 study with STC-15 in combination with Coherus’s next generation PD-1 inhibitor, LOQTORZI® (toripalimab). bit.ly/3Z5nlVv

Look out for the #STORM team at London Life Sciences Week! Our CEO, Jerry McMahon, will attend the upcoming @Jefferies London Healthcare Conference from 19-21 November alongside our CBO, Marguerite Hutchinson.


Check out the latest insights from our CEO, Jerry McMahon, featured in an article by International Clinical Trials discussing the current field of Alzheimer’s disease, drugs, biomarkers, and the future of treatment options for #neurogenerativediseases: bit.ly/3YJimc7

Read the press release here: bit.ly/3YYBaFy


Visit our poster presentation at #SITC2024! 📝 Title: Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced malignancies 📅 Date: Saturday 9 November 📌 Abstract number: 676

STORM is in Barcelona for the EORTC-NCI-AACR (#ENA) Symposium! Poster details below 👇 📢 Session Title: New therapies in immuno oncology 📅 Session Date and Time: 25 October, 09:00 - 15:00 CEST 🏢 Location: Exhibition Hall 📌 Catalog Number: 451 🗞️ Presentation Number: PB439

Thanks to @Cambridge_Uni for spotlighting us as one of '10 Cambridge spinouts changing the story of cancer'! Check out STORM in the article 👇 and discover how we are pioneering cellular reprogramming through RNA modifications to treat disease🧬#lifesciences #biotech #cancer
💡A brilliant idea for helping cancer patients is just that – an idea – until it is put into practice. Here's how 10 companies spun out of research at Cambridge are doing it: cam.ac.uk/stories/cambridge-… #ChangingTheStoryOfCancer

Read the press release here: bit.ly/481AC4x